首页 | 本学科首页   官方微博 | 高级检索  
检索        


PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study
Authors:Daniel P Petrylak MD  Nicholas J Vogelzang MD  Kamal Chatta MD  Mark T Fleming MD  David C Smith MD  Leonard J Appleman MD  PhD  Arif Hussain MD  Manuel Modiano MD  Parminder Singh MD  Scott T Tagawa MD  Ira Gore MD  Edward F McClay MD  Anthony E Mega MD  A Oliver Sartor MD  Bradley Somer MD  Raymond Wadlow MD  Neal D Shore MD  William C Olson PhD  Nancy Stambler DrPH  Vincent A DiPippo PhD  Robert J Israel MD
Institution:1. Department of Urology, Yale University, New Haven, Connecticut;2. Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada;3. Virginia Mason Medical Center, Seattle, Washington;4. Virginia Oncology Associates, Norfolk, Virginia;5. University of Michigan, Ann Arbor, Michigan;6. Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania;7. University of Maryland, Baltimore, Maryland;8. Arizona Clinical Research Center, Tucson, Arizona;9. Mayo Clinic, Phoenix, Arizona;10. Weill Cornell Medical College, New York, New York;11. Alabama Oncology, Birmingham, Alabama;12. California Cancer Associates for Research and Excellence, Encinitas, California;13. The Miriam Hospital, Providence, Rhode Island;14. School of Medicine, Tulane University, New Orleans, Louisiana;15. West Cancer Center and Research Institute, Memphis, Tennessee;16. Virginia Cancer Specialists, Fairfax, Virginia;17. Carolina Urologic Research Center, Myrtle Beach, South Carolina;18. Progenics Pharmaceuticals, Inc, New York, New York
Abstract:
Keywords:antibody-drug conjugate  mCRPC  prostate-specific membrane antigen
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号